BRPI0924307A2 - - Google Patents

Info

Publication number: BRPI0924307A2
Authority: BR; Brazil

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-19

Filing date

2009-12-18

Publication date

2017-08-22

2009-12-18 Application filed filed Critical

2017-08-22 Publication of BRPI0924307A2 publication Critical patent/BRPI0924307A2/pt

2017-12-12 Publication of BRPI0924307A8 publication Critical patent/BRPI0924307A8/pt

2020-05-05 Publication of BRPI0924307B1 publication Critical patent/BRPI0924307B1/pt

2021-05-25 Publication of BRPI0924307B8 publication Critical patent/BRPI0924307B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Physical Water Treatments (AREA)

BRPI0924307A 2009-02-19 2009-12-18 análogos de oxintomodulina BRPI0924307B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US2009/034448 WO2010096052A1 (en)	2009-02-19	2009-02-19	Oxyntomodulin analogs
PCT/US2009/068678 WO2010096142A1 (en)	2009-02-19	2009-12-18	Oxyntomodulin analogs

Publications (4)

Publication Number	Publication Date
BRPI0924307A2 true BRPI0924307A2 ( )	2017-08-22
BRPI0924307A8 BRPI0924307A8 (pt)	2017-12-12
BRPI0924307B1 BRPI0924307B1 (pt)	2020-05-05
BRPI0924307B8 BRPI0924307B8 (pt)	2021-05-25

Family

ID=42634127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0924307A BRPI0924307B8 (pt)	2009-02-19	2009-12-18	análogos de oxintomodulina

Country Status (23)

Country	Link
US (2)	US20120165503A1 ( )
EP (1)	EP2398483B1 ( )
JP (1)	JP5756961B2 ( )
KR (1)	KR101634139B1 ( )
CN (1)	CN102573872B ( )
AU (1)	AU2009340439B2 ( )
BR (1)	BRPI0924307B8 ( )
CA (1)	CA2754350C ( )
CL (1)	CL2011002036A1 ( )
CY (1)	CY1116917T1 ( )
DK (1)	DK2398483T3 ( )
ES (1)	ES2524477T3 ( )
HR (1)	HRP20141215T1 ( )
IL (1)	IL214729A ( )
MX (1)	MX2011008717A ( )
PE (1)	PE20120621A1 ( )
PL (1)	PL2398483T3 ( )
PT (1)	PT2398483E ( )
RU (1)	RU2542362C2 ( )
SG (1)	SG173791A1 ( )
SI (1)	SI2398483T1 ( )
WO (2)	WO2010096052A1 ( )
ZA (1)	ZA201106051B ( )

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2570133B1 (en)	2005-11-07	2016-03-23	Indiana University Research and Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
RU2477286C2 (ru)	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2009058662A2 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Glucagon antagonists
US8980830B2 (en)	2007-10-30	2015-03-17	Indiana University Research And Technology Corporation	Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
EP2300037B1 (en)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en)	2008-06-17	2009-12-23	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en)	2008-06-17	2015-11-16	Univ Indiana Res & Tech Corp	Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
CN102325539A (zh)	2008-12-19	2012-01-18	印第安纳大学研究及科技有限公司	基于酰胺的胰高血糖素超家族肽前药
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
AP3329A (en)	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina
EP2528618A4 (en)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
EA023925B1 (ru)	2010-04-27	2016-07-29	Зилэнд Фарма А/С	Пептидные конъюгаты агонистов рецептора glp-1 и их применение
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2580317C2 (ru)	2010-06-24	2016-04-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
WO2012150503A2 (en) *	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) *	2011-05-10	2012-11-15	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
PE20240686A1 (es)	2011-06-10	2024-04-10	Hanmi Science Co Ltd	Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) *	2011-06-17	2023-03-07	Hanmi Science Co Ltd	Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
BR112013032717A2 (pt)	2011-06-22	2017-01-24	Univ Indiana Res & Tech Corp	coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
MX2014005351A (es)	2011-11-03	2014-05-28	Zealand Pharma As	Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
RU2014117678A (ru) *	2011-11-17	2015-12-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
KR20150023690A (ko) *	2012-06-14	2015-03-05	사노피	엑센딘-4 펩타이드 유사체
CA2877358A1 (en)	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
AU2013295035B2 (en)	2012-07-23	2017-08-03	Zealand Pharma A/S	Glucagon analogues
KR101968344B1 (ko) *	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PE20151421A1 (es)	2012-11-06	2015-09-24	Hanmi Pharm Ind Co Ltd	Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) *	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP2016503046A (ja) *	2012-12-19	2016-02-01	ノヴォノルディスクアー／エス	コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN105189465B (zh)	2013-03-21	2019-02-26	赛诺菲-安万特德国有限公司	合成含有乙内酰脲的肽产物
WO2014147129A1 (en)	2013-03-21	2014-09-25	Sanofi-Aventis Deutschland Gmbh	Synthesis of cyclic imide containing peptide products
WO2014161835A1 (en)	2013-04-03	2014-10-09	Sanofi	Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
CN105792851B (zh) *	2013-09-13	2023-10-10	斯克利普斯研究所	修饰的治疗剂及其组合物
WO2015055801A1 (en)	2013-10-17	2015-04-23	Zealand Pharma A/S	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
MX2016005556A (es)	2013-11-06	2016-07-15	Zealand Pharma As	Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080155A1 (en)	2013-12-13	2016-10-19	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
AU2014364589B2 (en)	2013-12-18	2020-02-27	The California Institute For Biomedical Research	Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2015124612A1 (en) *	2014-02-18	2015-08-27	Novo Nordisk A/S	Stable glucagon analogues and use for treatment of hypoglycaemia
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) *	2014-09-23	2020-04-17	深圳市图微安创科技开发有限公司	胃泌酸调节素类似物
CR20170164A (es)	2014-10-24	2017-08-29	Merck Sharp & Dohme	Coagonistas de los receptores de glucagón y de glp-1
US10253078B2 (en)	2014-10-29	2019-04-09	Zealand Pharma A/S	GIP agonist compounds and methods
MY185334A (en) *	2014-12-30	2021-05-06	Hanmi Pharm Ind Co Ltd	Glucagon derivatives with improved stability
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
EA201890058A1 (ru) *	2015-06-30	2018-07-31	Ханми Фарм. Ко., Лтд.	Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3359191A4 (en)	2015-10-05	2019-05-29	Merck Sharp & Dohme Corp.	ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
WO2017062271A2 (en)	2015-10-06	2017-04-13	Merck Sharp & Dohme Corp.	Antibody drug conjugate for anti-inflammatory applications
WO2017074798A2 (en) *	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Long-acting co-agonists of the glucagon and glp-1 receptors
WO2017100107A2 (en) *	2015-12-09	2017-06-15	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and glp-1 receptors
WO2017116204A1 (ko)	2015-12-31	2017-07-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
EP3407916B1 (en)	2016-01-29	2023-12-20	Merck Sharp & Dohme LLC	Phosphonate linkers and their use to facilitate cellular retention of compounds
KR102005457B1 (ko) *	2016-06-29	2019-07-30	한미약품 주식회사	글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2017371516C1 (en)	2016-12-09	2021-09-02	Zealand Pharma A/S	Acylated GLP-1/GLP-2 dual agonists
CN108299553B (zh) *	2017-01-13	2021-07-16	博瑞生物医药（苏州）股份有限公司	胃泌酸调节素修饰物
CN106986924A (zh) *	2017-03-23	2017-07-28	中国药科大学	胃泌酸调节素（oxm）类似物及其应用
PL3670529T3 (pl) *	2017-08-16	2024-06-10	Dong-A St Co., Ltd.	Acylowany analog peptydowy oksyntomoduliny
WO2019060660A1 (en)	2017-09-25	2019-03-28	Merck Sharp & Dohme Corp.	CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS
CN120887972A (zh) *	2017-11-24	2025-11-04	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
CN109836504B (zh) *	2017-11-24	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的多结构域活性蛋白
WO2020098657A1 (zh) *	2018-11-12	2020-05-22	天津药物研究院有限公司	具有双重受体激动作用的胰高血糖素衍生肽及其用途
KR20210109552A (ko)	2018-12-21	2021-09-06	지앙수 헨그루이 메디슨 컴퍼니 리미티드	이중특이적 단백질
US11471512B2 (en)	2019-03-01	2022-10-18	Merck Sharp & Dohme Llc	Pharmaceutical compositions of a peptide
CN110684082B (zh) *	2019-10-08	2021-12-10	江苏诺泰澳赛诺生物制药股份有限公司	Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AU2020397917A1 (en)	2019-12-04	2022-06-23	The Scripps Research Institute	GLP2 receptor agonists and methods of use
EP3842060A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled triazole co-agonists of the glucagon and glp-1 receptors
KR102154959B1 (ko) *	2020-04-29	2020-09-10	동아에스티 주식회사	지속형 glp-1 및 글루카곤 수용체 이중작용제
KR102886870B1 (ko) *	2020-05-09	2025-11-18	톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디.	이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN112898405B (zh) *	2021-01-22	2023-02-28	深圳市图微安创科技开发有限公司	多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
MX2023014771A (es)	2021-06-09	2024-03-19	Scripps Research Inst	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CN119930789A (zh) *	2023-11-06	2025-05-06	成都奥达生物科技有限公司	一种gcg激动剂化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275152A (en) *	1977-02-03	1981-06-23	Eastman Kodak Company	Hydrolysis of protein-bound cholesterol esters
CA2452044A1 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
WO2003027637A2 (en)	2001-09-24	2003-04-03	Oregon Health And Science University	Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
EP1474163A2 (en) *	2002-01-10	2004-11-10	Imperial College Innovations Limited	Modification of feeding behavior
AU2003239478A1 (en) *	2002-06-04	2003-12-22	Eli Lilly And Company	Modified glucagon-like peptide-1 analogs
US7364875B2 (en) *	2003-10-30	2008-04-29	Cresent Innovations, Inc.	Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
RU2485135C2 (ru) *	2005-06-13	2013-06-20	Импиэриэл Инноувейшнс Лимитид	Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
CN101389648B (zh)	2006-02-22	2013-07-17	默沙东公司	肽胃泌酸调节素衍生物
CN106008699A (zh) *	2006-09-08	2016-10-12	Ambrx公司	经修饰的人类血浆多肽或Fc骨架和其用途
JP5231732B2 (ja)	2006-10-26	2013-07-10	株式会社東芝	冷却装置、およびこれを備えた電子機器
AU2008216265B2 (en) *	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
EP2300037B1 (en)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
CN102325539A (zh)	2008-12-19	2012-01-18	印第安纳大学研究及科技有限公司	基于酰胺的胰高血糖素超家族肽前药
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs

2009
- 2009-02-19 WO PCT/US2009/034448 patent/WO2010096052A1/en not_active Ceased
- 2009-12-18 SI SI200931091T patent/SI2398483T1/sl unknown
- 2009-12-18 PT PT98405947T patent/PT2398483E/pt unknown
- 2009-12-18 PL PL09840594T patent/PL2398483T3/pl unknown
- 2009-12-18 AU AU2009340439A patent/AU2009340439B2/en not_active Ceased
- 2009-12-18 EP EP09840594.7A patent/EP2398483B1/en active Active
- 2009-12-18 MX MX2011008717A patent/MX2011008717A/es active IP Right Grant
- 2009-12-18 HR HRP20141215AT patent/HRP20141215T1/hr unknown
- 2009-12-18 PE PE2011001525A patent/PE20120621A1/es not_active Application Discontinuation
- 2009-12-18 SG SG2011060183A patent/SG173791A1/en unknown
- 2009-12-18 WO PCT/US2009/068678 patent/WO2010096142A1/en not_active Ceased
- 2009-12-18 BR BRPI0924307A patent/BRPI0924307B8/pt not_active IP Right Cessation
- 2009-12-18 KR KR1020117021805A patent/KR101634139B1/ko not_active Expired - Fee Related
- 2009-12-18 CN CN200980158734.XA patent/CN102573872B/zh not_active Expired - Fee Related
- 2009-12-18 RU RU2011134596/04A patent/RU2542362C2/ru active
- 2009-12-18 US US13/202,524 patent/US20120165503A1/en not_active Abandoned
- 2009-12-18 DK DK09840594.7T patent/DK2398483T3/da active
- 2009-12-18 ES ES09840594.7T patent/ES2524477T3/es active Active
- 2009-12-18 CA CA2754350A patent/CA2754350C/en not_active Expired - Fee Related
- 2009-12-18 JP JP2011551052A patent/JP5756961B2/ja not_active Expired - Fee Related
2011
- 2011-08-17 ZA ZA2011/06051A patent/ZA201106051B/en unknown
- 2011-08-18 IL IL214729A patent/IL214729A/en active IP Right Grant
- 2011-08-19 CL CL2011002036A patent/CL2011002036A1/es unknown
2014
- 2014-12-18 CY CY20141101064T patent/CY1116917T1/el unknown
2015
- 2015-04-14 US US14/686,760 patent/US9593155B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PL2398483T3 (pl)	2015-03-31
WO2010096142A1 (en)	2010-08-26
JP2012518035A (ja)	2012-08-09
EP2398483B1 (en)	2014-09-24
HRP20141215T1 (hr)	2015-02-13
US20150307580A1 (en)	2015-10-29
SG173791A1 (en)	2011-10-28
CN102573872B (zh)	2016-03-23
CN102573872A (zh)	2012-07-11
AU2009340439A1 (en)	2011-09-15
DK2398483T3 (da)	2014-10-27
EP2398483A1 (en)	2011-12-28
CA2754350C (en)	2019-07-09
KR101634139B1 (ko)	2016-06-28
JP5756961B2 (ja)	2015-07-29
CL2011002036A1 (es)	2012-02-03
SI2398483T1 (sl)	2015-01-30
CA2754350A1 (en)	2010-08-26
US9593155B2 (en)	2017-03-14
KR20120068755A (ko)	2012-06-27
PE20120621A1 (es)	2012-06-08
BRPI0924307A8 (pt)	2017-12-12
IL214729A0 (en)	2011-11-30
US20120165503A1 (en)	2012-06-28
EP2398483A4 (en)	2013-03-06
RU2542362C2 (ru)	2015-02-20
CY1116917T1 (el)	2017-04-05
ZA201106051B (en)	2014-07-30
ES2524477T3 (es)	2014-12-09
BRPI0924307B8 (pt)	2021-05-25
IL214729A (en)	2016-06-30
AU2009340439B2 (en)	2015-07-16
HK1165333A1 (en)	2012-10-05
RU2011134596A (ru)	2013-03-27
BRPI0924307B1 (pt)	2020-05-05
WO2010096052A1 (en)	2010-08-26
PT2398483E (pt)	2014-12-04
MX2011008717A (es)	2012-09-28

Publication	Publication Date	Title
BE2015C040I2 ( )	2024-10-08
BRPI0925311A2 ( )	2016-02-02
BR112012008195A2 ( )	2021-11-03
BR112012003062A2 ( )	2017-05-02
BRPI0924307A2 ( )	2017-08-22
BRPI1006562A2 ( )	2017-08-22
BR112012008267A2 ( )	2021-11-03
BR112012012396A2 ( )	2021-11-03
BR112012000607A2 ( )	2017-09-05
BR122021004633A2 ( )	2020-10-13
BR112012000665A2 ( )	2017-09-05
BR112012012487A2 ( )	2021-11-23
BR112012003080A2 ( )	2017-09-12
BR112012003853A2 ( )	2017-08-29
BRPI0924534A2 ( )	2021-12-07
BR112012009797A2 ( )	2017-09-05
BR112012012080A2 ( )	2021-11-03
BR112012009446A2 ( )	2021-12-07
BR112012009703A2 ( )	2017-09-05
BRPI1005795A2 ( )	2017-08-29
BR112012010357A2 ( )	2017-10-03
BR112012001263A2 ( )	2017-08-15
BR112012007656A2 ( )	2017-09-12
BRPI1004942A2 ( )	2017-08-08
BR112012000159A2 ( )	2017-08-15

Legal Events

Date	Code	Title	Description
2017-12-12	B25A	Requested transfer of rights approved	Owner name: MERCK SHARP AND DOHME CORP. (US) , INDIANA UNIVERS Owner name: MERCK SHARP AND DOHME CORP. (US) , INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) , MSD ITALIA S.R.L. (IT)
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-01-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-20	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-03-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-05-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-10-25	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2023-02-14	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.